Title:
BIOMARKER FOR PREDICTING RESPONSE TO IMMUNE CHECKPOINT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2023/022200
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a method for predicting the response to an immune checkpoint inhibitor and a method for predicting the prognosis of a cancer patient treated with an immune checkpoint inhibitor. The present invention provides a method for predicting the response to an immune checkpoint inhibitor using the amount of IL-1 signaling pathway molecules in a subject, who needs a cancer treatment, as an indicator. The present invention also provides a method for predicting the prognosis of a cancer patient treated with an immune checkpoint inhibitor, wherein the prognosis is predicted using the amount of IL-1 signaling pathway molecules in the aforesaid subject as an indicator.
More Like This:
Inventors:
AMEMIYA TAKAHIRO (JP)
HONMA MASASHI (JP)
KARIYA YOSHIAKI (JP)
SUZUKI HIROSHI (JP)
HONMA MASASHI (JP)
KARIYA YOSHIAKI (JP)
SUZUKI HIROSHI (JP)
Application Number:
PCT/JP2022/031229
Publication Date:
February 23, 2023
Filing Date:
August 18, 2022
Export Citation:
Assignee:
UNIV TOKYO (JP)
International Classes:
G01N33/68
Foreign References:
| JP2020525758A | 2020-08-27 | |||
| JP2018516884A | 2018-06-28 | |||
| US20210063398A1 | 2021-03-04 | |||
| JP2020527332A | 2020-09-10 |
Other References:
EFIMIA BOUTSIKOU, DOMVRI KALLIOPI, HARDAVELLA GEORGIA, TSIOUDA DORA, ZAROGOULIDIS KONSTANTINOS, KONTAKIOTIS THEODOROS: "Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice", THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, SAGE PUBLISHING, vol. 10, 1 January 2018 (2018-01-01), XP055645231, ISSN: 1758-8359, DOI: 10.1177/1758835918768238
BRESLER SCOTT C, MIN LE, RODIG SCOTT J, WALLS ANDREW C, XU SHUYUN, GENG SONGMEI, HODI F STEPHEN, MURPHY GEORGE F, LIAN CHRISTINE G: "Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC., vol. 97, no. 2, 1 February 2017 (2017-02-01), The United States and Canadian Academy of Pathology, Inc. , pages 207 - 216, XP093036105, ISSN: 0023-6837, DOI: 10.1038/labinvest.2016.126
BRESLER SCOTT C, MIN LE, RODIG SCOTT J, WALLS ANDREW C, XU SHUYUN, GENG SONGMEI, HODI F STEPHEN, MURPHY GEORGE F, LIAN CHRISTINE G: "Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC., vol. 97, no. 2, 1 February 2017 (2017-02-01), The United States and Canadian Academy of Pathology, Inc. , pages 207 - 216, XP093036105, ISSN: 0023-6837, DOI: 10.1038/labinvest.2016.126
Attorney, Agent or Firm:
FIELDS IP ATTORNEYS PPC (JP)
Download PDF:
Previous Patent: NEAR-INFRARED LIGHT TRANSMITTING BLACK PARTICLES
Next Patent: RELIEF STRUCTURE-BEARING TRANSFER FOIL
Next Patent: RELIEF STRUCTURE-BEARING TRANSFER FOIL